Trial · NCT07904546
ADBest TREAT Registry
NCT07904546, Recruiting, Universitätsklinikum Hamburg-Eppendorf
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ADBest TREAT Registry. Trials, record NCT07904546. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904546
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ADBest TREAT Registry
- NCT number
- NCT07904546
- Status
- Recruiting
- Enrollment
- 5,000 participants, estimated
- Lead sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Conditions
- Atopic Dermatitis
- Interventions
- Abrocitinib, Baricitinib, Upadacitinib, Dupilumab, Lebrikizumab, Nemolizumab, Tralokinumab, Conventional Systemic Therapy
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Eczema Area and Severity Index(EASI) score | At registry inclusion (week 0),at weeks 16,28, and 52 ,and every 24 weeks thereafter through 60 months. | Atopic dermatititis severity will be assessed by the physician using the Eczema Area and Severity Index (EASI).The score ranges from 0 to 72 ,with higher scores indicating greater disease severity. |
| Primary | Dermatology Life Quality Index (DLQI) score | At registry inclusion (week 0),at weeks 16,28, and 52 ,and every 24 weeks thereafter through 60 months;an additional visit during weeks 0-4 may occur optionally. | Quality of life will be assessed using the 10 -item Dermatology Life Quality Index.(DLQ),referring to the previous week.Total score ranges from 0 to 30 ;Higher scores indicates greater impairement of quality of life. |
| Secondary | Physician-reported clinical phenotype and affected body sites | At inclusion;phenotype and disease course updated as needed.Body -site involvement assessed at registry inclusion (week 0) at weeks 16,28,and 52 ,then every 24 weeks through months 60. | Clinical phenotype and affected body sites are documented by the physician using the online eCRF, including disease course, clinical subtype, and current eczematous involvement of predefined anatomical areas. |
| Secondary | Atopic Dermatitis-related Pain Intensity | At registry inclusion(week 0),at weeks 16,28, and 52 ,and every 24 weeks thereafter through month 60. | Pain intensity during 24 hours,rated by the patient on a 0-10 scale (0=no pain;10=worst imaginable pain).Higher scores indicate more pain. |
| Secondary | Physician-reported Adverse Events During Routine Care | At weeks 16,28, and 52, then every 24 weeks through month 60,and at unscheduled visits when applicable. | Adverse events are documented by treating physicians in the online electronic case report form (eCRF) during routine care. Results will be reported as the number and percentage of participants with at least one documented adverse event;event type and severity will be reported when available. |
| Secondary | Physician/Investigator Global Assessment( PGA/IGA). | At registry inclusion(week 0),at weeks 16,28, and 52 ,and every 24 weeks thereafter through month 60. | Atopic dermatitis severity is assessed by the physician using the Physician /Investigator Global Assessment (PGA/IGA).Scores range from 0 to 5 :0=clear,1=almost clear,2=mild,3=moderate,4=severe, and 5 =very severe.Higher scores indicate greater disease severity. |
| Secondary | Sleep impairment | At registry inclusion(week 0),at weeks 16,28, and 52 ,and every 24 weeks thereafter through month 60. | Atopic dermatitis-related sleep impairment during the previous night,rated by the patient on a 0-10 scale (0=no impairment;10=extreme impairment).Higher scores indicate greater impairment. |
| Secondary | Patient-assessed atopic dermatitis severity | At registry inclusion(week 0),at weeks 16,28, and 52 ,and every 24 weeks thereafter through month 60. | Current disease severity reported by the patient as clear,almost clear,mild,moderate ,severe,or very severe. |
| Secondary | Patient-reported disease control | At weeks 16,28, and 52 ,and every 24 weeks thereafter through month 60. | Number of weeks during the previous 12 weeks in which atopic dermatitits was well controlled,reported by the patient(0-12 weeks). |
| Secondary | Patient satisfaction with treatment | At weeks 16,28, and 52 ,and every 24 weeks thereafter through month 60. | Patient satisfaction with medical care and atopic dermatitis treatment during the previous 3 months,rated on a 0-10 scale(0=very dissatisfied,10=very satisfied). |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904546
GET https://conductscience.org/api/trials/v1/NCT07904546/registered